Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Dexclamol

From Wikipedia, the free encyclopedia

Dexclamol
Clinical data
Other namesAY 24169
Identifiers
  • (1R,6R,8R)-6-propan-2-yl-3-azapentacyclo[11.8.1.03,8.09,22.016,21]docosa-9,11,13(22),16,18,20-hexaen-6-ol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H29NO
Molar mass347.502 g·mol−1
3D model (JSmol)
  • CC(C)[C@]1(CCN2C[C@@H]3C4=CC=CC=C4CCC5=C3C(=CC=C5)[C@H]2C1)O
  • InChI=1S/C24H29NO/c1-16(2)24(26)12-13-25-15-21-19-8-4-3-6-17(19)10-11-18-7-5-9-20(23(18)21)22(25)14-24/h3-9,16,21-22,26H,10-15H2,1-2H3/t21-,22-,24-/m1/s1
  • Key:UPMOVJBGNREKJV-CQOQZXRMSA-N

Dexclamol (AY 24169) was an investigational new drug developed by McKenna and Harrison, Ltd. that was evaluated as a antipsychotic.[1][2][3][4] It acts as a dopamine receptor antagonist.[1]

See also

[edit]

References

[edit]
  1. 1 2 Humber LG, Bruderlein FT, Voith K (November 1975). "Neuroleptic agents of the benzocycloheptapyridoisoquinoline series. A hypothesis on their mode of interaction with the central dopamine receptor". Molecular Pharmacology. 11 (6): 833–840. doi:10.1016/S0026-895X(25)10694-9. PMID 1239657.
  2. Elks J, Ganellin CR, eds. (1990). Dictionary of Drugs. Springer US. doi:10.1007/978-1-4757-2085-3. ISBN 978-1-4757-2087-7.
  3. Castañer J, Paton DM (1976). "Dexclamol hydrochloride". Drugs of the Future. 1 (8): 366. doi:10.1358/dof.1976.001.08.1002521.
  4. US 3657250, Bruderlein FT, Humber LG, "Benzocycloheptaisoquinoline derivatives", assigned to Ayerst Mckenna and Harrison Inc.